December 7, 2011Open Access

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Baselga et al. (Wed,) studied this question.

synapsesocial.com/papers/69dd1ef03ffc04feac1334c3 https://doi.org/https://doi.org/10.1056/nejmoa1113216

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.1994 · 518 citations
2Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.2001 · 775 citations
3Untangling the ErbB signalling network2001 · 6,932 citations
4Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy2010 · 639 citations
5Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy2010 · 764 citations

Bookmark

View Full Paper